Current Esketamine News and Events

Current Esketamine News and Events, Esketamine News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 1 | 8 Results
Researchers uncover new information on the effects of antidepressants
The findings of a new study challenge the prevailing thinking on the primary role of serotonin and other neurotransmitters in the effects of antidepressants. (2021-02-18)

McLean hospital study examines the cost-effectiveness of esketamine
A paper authored by researchers from McLean Hospital has determined that esketamine, a nasal spray to treat severe depression, is currently too expensive for widespread use. (2020-07-13)

Ef­fects of rapid-act­ing an­ti­de­press­ants con­sol­id­ated in sleep?
Ketamine alleviates depressive symptoms within hours, with the most significant change typically seen a day after its administration. However, the symptoms often reappear within a week. According to researchers at the University of Helsinki, neural connections strengthened by the quick treatment of depression are consolidated in the brain during the deep sleep periods of the following night. To prevent the circle of negative thoughts regaining supremacy, depressed patients also need therapy. (2020-04-22)

Side effects mild, brief with single antidepressant dose of intravenous ketamine
Researchers found that a single, low-dose ketamine infusion was relatively free of side effects for patients with treatment-resistant depression. Widespread off-label use of intravenous subanesthetic-dose ketamine has raised concerns about side effects, especially given its history as a drug of abuse. The most common short-term side effect of the rapid-acting treatment was 'feeling strange or loopy.' (2019-11-18)

Simple injection of air proves successful in releasing child's tongue trapped in bottle, inspired by opening a wine bottle
A relatively simple injection of air has proved successful in releasing a 7-year-old boy's tongue that became entrapped in a juice bottle, says new research published in the latest edition of the European Journal of Anaesthesiology (the official journal of the European Society of Anaesthesiology). (2019-10-31)

Study supports effectiveness of new fast-acting antidepressant, esketamine nasal spray
New research supports the effectiveness and safety of esketamine nasal spray in treating depression in people who have not responded to previous treatment. The research will be published online today in the American Journal of Psychiatry. This study is one of the key studies that led to the recent Food and Drug Administration (FDA) approval of esketamine nasal spray, in conjunction with an oral antidepressant, for use in people with treatment-resistant depression. (2019-05-21)

Study shows fast-acting benefits of ketamine for depression and suicidality
A nasal spray formulation of ketamine shows promise in the rapid treatment of symptoms of major depression and suicidal thoughts, according to a new study published online today in The American Journal of Psychiatry (AJP). The double-blind study compared the standard treatment plus an intranasal formulation of esketamine, part of the ketamine molecule, to standard treatment plus a placebo for rapid treatment of symptoms of major depression, including suicidality, among individuals at imminent suicide risk. (2018-04-16)

Antidepressant response within hours? Experts weigh evidence on ketamine as fast-acting treatment for depression in Harvard Review of Psychiatry
Recent studies suggest that ketamine, a widely used anesthetic agent, could offer a wholly new approach to treating severe depression -- producing an antidepressant response in hours rather than weeks. Two reviews of recent evidence on ketamine and related drugs for treating depression appear in the Harvard Review of Psychiatry, published by Wolters Kluwer. (2018-02-22)

Page 1 of 1 | 8 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.